NPPB and hydrops fetalis: Like the APOLLO-B trial, inclusion criteria required either a biopsy-proven diagnosis of ATTR-CM or the fulfilment of non-invasive diagnostic criteria, and a history of HF with baseline NT-proBNP greater than 300 ng/L (600 ng/L in atrial fibrillation) but lower than 8500 ng/L.